Real-world use of efgartigimod in acetylcholine receptor antibody–positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus

This study describes how efgartigimod is integrated into routine clinical practice as part of longitudinal disease management for AChR antibody-positive gMG. Real-world use encompassed diverse clinical scenarios and required individualized retreatment decisions and ongoing reassessment. These findings highlight the role of FcRn blockade as a flexible therapeutic option that complements established therapy in everyday care.